您的账号已在其他设备登录,您当前账号已强迫下线,
如非您本人操作,建议您在会员中心进行密码修改

确定

非小细胞肺癌靶向治疗主要靶点及其检测方法进展

Therapeutic targets and corresponding detection methods of target therapy for non-small cell lung cancer

摘要:

驱动基因突变是非小细胞肺癌的主要致病因素之一,靶向治疗正是针对驱动基因突变,不同的突变类型对靶向药物的敏感性不同,根据基因的变异情况选择靶向药物至关重要。当前可用于指导非小细胞肺癌靶向治疗的目标基因越来越多,可用于检测相关基因的方法与试剂也越来越多,临床上需要精准选择合适的检测靶点与方法。本文根据国家药品管理监督局批准的相关基因检测试剂,就非小细胞肺癌靶向治疗相关突变基因靶点及检测试剂进行综述,为临床选择适宜的检测方法与试剂提供参考,从而更好地为非小细胞肺癌患者靶向治疗提供精准伴随诊断。

更多
abstracts:

Driver gene mutation is one of the most important cause of non-small cell lung cancer (NSCLC), as well as the drug target of target therapy. Patients with different driver mutations have different sensitivity to target therapy drug. So it is crucial to select target drug according to respective driver mutation. Nowadays more and more driver mutation detection come into clinical use for the guidance of NSCLC target therapy as well as more detection methods and commercial reagents were developed and utilized. Clinical and laboratory staff should be more cautious to select appropriate detection targets and reagents. Therefore, the relative target driver mutation and detection reagents in target therapy of NSCLC were reviewed in this paper, according to the China National Medical Products Administration, in order to provide reference for better selection of adequate methods and reagents as well as provide advice for personalized therapy of NSCLC patients.

More
作者: 邵璇璇 [1] 高春芳 [2] 贾健安 [1]
作者单位: 解放军联勤保障部队第九○一医院检验科,合肥 230031 [1] 海军军医大学附属东方肝胆外科医院实验诊断科,上海 200438 [2]
期刊: 《中华检验医学杂志》2020年43卷8期 842-848页 ISTICPKUCSCDCA
栏目名称: 继续教育
DOI: 10.3760/cma.j.cn114452-20200305-00189
发布时间: 2020-09-15
  • 浏览:16
  • 下载:8

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!